Endocrinology, Type 2-Diabetes
27. May 2011
Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy
BACKGROUND:
Treatment of patients with perioxisome proliferator-activated receptor-γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator-activated receptor-γ agonists has not been established in a cl…
Read the publication
Journal:
Authors:
- Henriksen K,
- Byrjalsen I,
- Qvist P,
- Beck-Nielsen H,
- Hansen G,
- Riis BJ,
- Perrild H,
- Svendsen OL,
- Gram J,
- Karsdal MA,
- Christiansen C,
- BALLET Trial Investigators,